

Medtronic

MAR 1 8 2011

510(K) SUMMARY

Date Prepared:

March 7, 2011

Trade Name of Device:

Achieve[™] Mapping Catheter

Common Name:

Catheter, electrode recording, or probe, electrode

recording

Classification:

Class II, 21 CFR 870.1220, Electrode Recording

Catheter

Applicant:

Medtronic Ablation Frontiers 2210 Faraday Avenue, Suite 100 Carlsbad, CA 92008 USA

Tel: 760-827-0007 Fax: 760-827-0020

Contact Person:

Brenda Clay

Regulatory Affairs

Predicate Devices:

ProMap[™], ProRhythm Lasso[™], Biosense Webster

Device Description:

The AchieveTM diagnostic mapping catheter is an intra-cardiac electrophysiology recording catheter and can be used for cardiac stimulation during electrophysiology studies. The distal mapping section of the Achieve catheter is a circular loop with eight evenly spaced electrodes to map electrical conduction within the atrium. The Achieve catheter should only be used with the corresponding electrical cable for Achieve. The Achieve catheter is available with two distal loop diameter sizes described in the following table:

Model	Loop Diameter
990063-015	15 mm
990063-020	20 mm

The sterile, single use only Electrical Cable (Model 990066) provides the conduction elements from the proximal end of the Achieve Catheter handle to standard shielded ECG pins that connect into standard electrophysiology recording and pacing equipment.

Indications for Use:

The Medtronic Ablation Frontiers Achieve Mapping Catheter is indicated for multiple electrode electrophysiological mapping of the cardiac structures of the heart, i.e. recording or stimulation only. The Achieve Catheter is designed to obtain electrograms in the atrial regions of the heart.

Contraindications:

The catheter is contraindicated as follows:

· For use as an ablation device



- For use with transeptal sheaths featuring side holes larger than 1.00 mm in diameter
- Retrograde approach

Electrophysiology studies are contraindicated when the patient's underlying cardiac disease makes it likely that induced arrhythmias will be extremely difficult to terminate and carry a high risk of death, as in the following conditions:

- An active systemic infection
- Left atrial thrombus
- Pulmonary vein stents
- Prosthetic heart valve (tissue or mechanical)
- Myxoma
- Interatrial baffle or patch
- Conditions where the manipulation of the catheter within the heart would be unsafe
- Acute myocardial infarction

Technological Characteristics of the Device Compared to the Predicate Device:

The Achieve Mapping Catheter uses similar technology, has similar intended use, functions, materials and method of operation as the following predicate device(s):

Table 5-1: Characteristic Comparison

Device	Achieve Catheter	ProMap Catheter	Lasso Catheter
	(Subject Device)	<u> </u>	
Intended Use	Map intracardiac	Map intracardiac	Map intracardiac
	structures of the heart	structures of the heart	structures of the heart
Indications for Use	The Achieve is indicated	The ProRhythm ProMap is	The LASSO Catheter is
	for multiple electrode	to be used for the	indicated for multiple
	electrophysiological	evaluation of cardiac	electrode
	mapping of cardiac	arrhythmias from	electrophysiological
	structures (i.e., recording	endocardial and	mapping of cardiac
	and stimulation only). The	intravascular sites. The	structures (i.e., recording
	Achieve Catheter is	ProMap coaxial mapping	and stimulation only). The
-	designed to obtain	Catheter is typically used	LASSO Catheter is
	electrograms in the atrial	in Electrophysiology	designed to obtain
	regions of the heart.	clinical procedures.	electrograms in the atrial
			regions of the heart.
Catheter Body Tubing	Pebax (distal body)	Unknown	Pebax
	Stainless Steel (proximal)		
Diameter	3.3F	3F	3F
Effective Length	146cm	60 – 125cm	143cm
Number of Electrodes	8	6	10 or 20
Distal End Shape	Circular Loop	Circular Loop	Circular Loop
Loop Diameter	15 and 20mm	15 to 25mm	15 to 25mm
Loop Material	Nitinol insulated with PET (Pebax covered)	Nitinol	Unknown
Delivered through a delivery catheter	Yes	Yes	Yes

Note: Materials in the predicate devices are not known with certainty. Material equivalence is demonstrated by *in vivo* performance tests and biocompatibility tests to FDA recognized standards.



Summary of Studies:

In vitro bench testing and *in vivo* testing have been performed on the device materials and finished devices. Performance, sterilization and biocompatibility testing verified that the Achieve Mapping Catheter performs as designed and is suitable for its intended use.

Performance testing included the following:

- Torquer / Introducer: insertion testing
- Rotational motion
- Insertion and retraction with compatible delivery device
- Insertion/retraction cycling
- Loop rotation
- Rotational loading
- Electrode contact sufficient for mapping
- Atraumatic tip
- Stiffness / flexibility / buckling
- Flexion fatigue
- Torque to failure
- Simulated use testing
- Electrical testing and electrical safety testing (ISO 60601-1:2006)
- Tensile testing (ISO 10551-1:2009)
- Loop integrity
- · Connector fatigue
- Corrosion resistance (ISO 10555-1:2009)

Biocompatibility testing included the following:

- Cytotoxicity (ISO 10993-5:2009)
- Sensitization (ISO 10993-10:2002, Amend 2006)
- Intracutaneous reactivity (ISO10993-10:2002, Amend 2006))
- Systemic toxicity (ISO 10993-11:2006)
- Pyrogenicity (ISO10993-11:2006)
- Hemolysis (ISO 10993-4:2002)
- Complement activation (ISO 10993-4:2002)
- Partial thromboplastin time (PPT) (ISO 10993-4:2002)
- Platelet and leukocyte count (ISO 10993-4:2002)

The Cable has been tested and is considered safe and effective per applicable parts of BS EN 60601-1 (2006, Medical electrical equipment – Part 1: General requirements for basic safety and essential performance).

Conclusion:

The data presented in this submission demonstrate that the Ablation Frontiers Achieve Mapping Catheter is substantially equivalent to the predicate devices identified in regards to device design, materials, and intended use.



Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002

Medtronic Ablation Frontiers c/o Ms. Brenda Clay Regulatory Affairs Specialist 2210 Faraday Avenue, Suite 100 Carlsbad, CA 92008

MAR 1 8 2011

Re: K102588

Trade Name: Achieve Mapping Catheter Regulation Number: 21 CFR 870.1220

Regulation Name: Electrode Recording Catheter

Regulatory Class: Class II (two)

Product Code: DRF Dated: March 11, 2011 Received: March 14, 2011

Dear Ms. Clay:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Page 2 – Ms. Brenda Clay

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours.

Bram D. Zuckerman, M.D.

Director

Division of Cardiovascular Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure



4. INDICATIONS FOR USE STATEMENT

510(K) Number (i	f known):		•
Device Name: M	edtronic Achieve™ Ma	apping Catheter	
Indications for Us	e:	·	
electrophysiologic		liac structures of the he	s indicated for multiple electrode eart, i.e. recording or stimulation only. The largions of the heart.
Prescription Use (21 CFR 801 Subp		AND/OR	Over-the-Counter Use(21 CFR 801 Subpart C)
(PLEASE DO NO	T WRITE BELOW T	HIS LINE-CONTINU	E ON ANOTHER PAGE IF NEEDED)
Concurrence of Cl	DRH, Office of Device	e Evaluation (ODE)	
Ľ.	indian Sign-Off) of Cardiov Ιθικ, NumberΚ	•	